IDEAYA Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Hi, everyone. It's Alethia Young here. I cover large cap, small and mid-cap biotech at Cantor. We have IDEAYA Biosciences. We have Yujiro Hata, who is the President and CEO; and we have Paul Stone, who is the SVP and CFO. We'll be doing a fireside chat for most of the conversation today.
Questions & Answers
So to start off, maybe can you just discuss IDEAYA's vision and how it originated? In general, what has the Company accomplished to date?
Sure, happy to. Thank you, Alethia, for the introduction and thank you to Cantor for the opportunity to participate today.
So IDEAYA was founded just over 6 years ago with a core focus to build the leading synthetic lethality-focused precision medicine oncology company. And since that time, we advanced two programs into the clinic: IDE397, which we believe is a potential best-in-class MAT2A inhibitor, targeting a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
